Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Wiener Medizinische Wochenschrift (1946)|December 25, 2007
["Targeted Therapies" in NSCLC - present and future]Georg Pall, Wolfgang HilbeTranslational Lung Cancer Research|March 26, 2015
Targeting angiogenesis in lung cancer - Pitfalls in drug developmentWolfgang Hilbe, Christian Manegold, Andreas PircherOnkologie|May 18, 2011
Cancer stem cells: characteristics and their potential role for new therapeutic strategiesStephan R Bohl, Andreas Pircher, Wolfgang HilbeLung Cancer (Amsterdam, Netherlands)|February 20, 2010
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patientsAndreas Pircher, Ferdinand Ploner, Helmut Popper, et al.Clinical Lung Cancer|February 10, 2015
Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth ConsideringFlorian Kocher, Michael Fiegl, Michael Mian, et al.Current Cancer Drug Targets|July 20, 2006
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promisesJutta Auberger, Judith Loeffler-Ragg, Walter Wurzer, et al.Cancer Detection and Prevention|October 28, 2006
Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancerVeronika F E Zech, Margit Dlaska, Alexandar Tzankov, et al.Oncology|August 26, 2015
NSCLC without Antineoplastic Treatment: Incidence, Characteristics, and Outcome as Outlined in the TYROL StudyFlorian Kocher, Fabian Lunger, Andreas Pircher, et al.Stem Cell Reviews and Reports|November 19, 2011
Endothelial progenitor cells: current issues on characterization and challenging clinical applicationsThomas Resch, Andreas Pircher, Christian M Kähler, et al.Virchows Archiv : an International Journal of Pathology|August 5, 2009
Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected casesWilliam Sterlacci, Michael Fiegl, Wolfgang Hilbe, et al.Pageof 7